An Apolipoprotein A-I gene promoter polymorphism associated with cognitive decline, but not with Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 25, Issue 2, 2008, Pages 97-102

  Helbecque, Nicole ^a   Codron, Valérie ^a   Cottel, Dominique ^a   Amouyel, Philippe ^a,b,c  

^a INSERM   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Alzheimer's disease; Apolipoprotein; Apolipoprotein A I; Association study; Genetic polymorphism

Indexed keywords

AGED; ALLELE; ALZHEIMER DISEASE; APOLIPOPROTEIN A 1 GENE; ARTICLE; CHOLESTEROL METABOLISM; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN A-I; CHROMOSOMES, HUMAN, PAIR 11; COGNITION DISORDERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 38849155723     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112176     Document Type: Article

References (25)

1. Caselli RJ, Beach TG, Yaari R, Reiman EM: Alzheimer's disease a century later. J Clin Psychiatry 2006;67:1784-1800.
2. Goedert M, Spillantini MG: A century of Alzheimer's disease. Science 2006;314:777-781.
3. Jellinger KA, Mitter-Ferstl E: The impact of cerebrovascular lesions in Alzheimer disease - a comparative autopsy study. J Neurol 2003;250:1050-1055.
4. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN: Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006;11:721-736.
5. Hoglund K, Wallin A, Blennow K: Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. Acta Neurol Scand 2006;185:87-92.
6. Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A: Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand 2006;185:63-70.
7. Liu HC, Hu CJ, Chang JG, Sung SM, Lee LS, Yuan RY, Leu SJ: Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord 2006;21:155-161.
8. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
9. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T: Comparative proteomics of cerebrospinal fluid in neuropathologically confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006;28:155-163.
10. Saczynski JS, White L, Peila RL, Rodriguez BL, Launer LJ: The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am J Epidemiol 2007;165:985-992.
11. Merched A, Xia Y, Visvikis S, Serot JM, Siest G: Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 2000;21:27-30.
12. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P: Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003;118:140-146.
13. Kamboh MI, Aston CE, Nestlerode CM, McAllister AE, Hamman RF: Haplotype analysis of two APOA1/ Msp I polymorphisms in relation to plasma levels of apo A-I and HDL cholesterol. Atherosclerosis 1996;127:255-262.
14. Juo SH, Wyszynski DF, Beaty TH, Huang HY, Bailey-Wilson JE: Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: a meta-analysis. Am J Med Genet 1999;82:235-241.
15. Danek GM, Valenti M, Baralle FE, Romano M: The A/G polymorphism in the -78 position of the apolipoprotein A-I promoter does not have a direct effect on transcriptional efficiency. Biochim Biophys Acta 1998;1398:67-74.
16. Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, Schulz A, Maier W, Kolsch H: APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann Neurol 2005;58:436-441.
17. Amouyel P, Richard F, Cottel D, Amant C, Codron V, Helbecque N: The deletion allele of the angiotensin I converting enzyme gene as a genetic susceptibility factor for cognitive impairment. Neurosci Lett 1996;217:203-205.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
19. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
20. Jia L, Bai H, Fu M, Xu Y, Yang Y, Long S: Relationship between plasma HDL subclasses distribution and apoA-I gene polymorphisms. Clin Chim Acta 2005;360:37-45.
21. Panza F, D'Introno A, Colacicco AM, Capurso C, Parigi AD, Capurso SA, Caselli RJ, Pilotto A, Scafato E, Capurso A, Solfrizzi V: Cognitive frailty: predementia syndrome and vascular risk factors. Neurobiol Aging 2006;27:933-940.
22. Ganguli M, Dodge HH, Shen C, DeKosky ST: Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 2004;63:115-121.
23. Feldman HH, Jacova C: Mild cognitive impairment. Am J Geriatr Psychiatry 2005;13:645-655.
24. Visser PJ, Kester A, Jolles J, Verhey F: Tenyear risk of dementia in subjects with mild cognitive impairment. Neurology 2006;67:1201-1207.
25. DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, Jagust W: Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004;63:220-227.